We are science visionaries who want to end cancer’s reign.

Approximately 10 million lives are lost to cancer annually, making it the second leading cause of death worldwide. Progress is happening – but is excruciatingly slow. Conventional approaches have reached their limits in producing safer and more powerful therapies.

At BioCopy, we focus on intracellular pHLA targets, one of the most challenging yet promising target classes in oncology. pHLA complexes are the molecular fingerprints of diseased cells, but they have been notoriously difficult to drug with conventional methods. With our proprietary AI-driven platform, we overcome these hurdles and open the door to highly specific, next-generation cancer biotherapeutics.

We address the decisive bottlenecks of drug discovery and development:

• An extremely difficult, tedious, and costly discovery and development process
• High failure rates when moving from discovery to industrial-scale production
• A critical risk that current biotherapeutics not only kill cancer cells but also damage healthy cells, causing life-threatening side effects

By enabling accurate recognition of cancer-specific pHLA targets, our platform dramatically increases precision, reduces risk, and accelerates the delivery of breakthrough cancer therapies.

We are cancer’s nemesis

Cancer often seems one step ahead of medicine, evolving too quickly and outsmarting human biology. This is not true. The body’s own immune system is an extremely powerful weapon against cancer cells. However, tumors are highly skilled at hiding from immune surveillance.

To overcome this, special biotherapeutics are needed: drugs that can guide immune cells directly to cancer cells and unleash their full power. These complex molecules act as matchmakers, recognizing tumor cells and linking them to immune effectors.

The challenge: discovering and developing such biotherapeutics is tedious, costly, and error-prone. And with current technologies, recognition is far from perfect. The risk remains high that healthy cells are targeted along with cancer cells, leading to dangerous side effects.

Where BioCopy makes the difference

This is where BioCopy comes in. We are the world’s first research-based biotechnology company to unlock the pHLA (peptide–HLA) target space with an AI-driven, end-to-end automated platform. pHLA complexes are the hidden molecular fingerprints of diseased cells - highly promising but historically inaccessible to drug discovery.

Our proprietary ValidaTe platform integrates AI, large-scale peptide screening, and automated validation to overcome this barrier. The result:

• Highly specific drug candidates that recognize cancer cells more accurately than ever before
• Reduced off-target risks, leading to safer therapies
• Faster, more reliable discovery compared to conventional approaches

By precisely targeting pHLA, we unleash the immune system’s power on a scale never seen before.

› Learn more about our pipeline of next-generation biotherapeutics.

Powerful drug candidates beyond cancer

One of BioCopy’s key advantages is that our platform is not limited to oncology. Because it targets the fundamental pHLA biology of diseased cells, it holds the potential to deliver powerful drug candidates for other severe conditions.

Our longer-term vision is to expand beyond cancer and apply our AI-driven discovery platform to immunological and neurological disorders, paving the way for next-generation biotherapeutics with broad, life-changing impact.

BioCopy was founded in 2019. Our technology was quickly recognized as leading-edge in early drug discovery, drug candidate safety and efficacy assessments. When we joined forces with Perspix BioTech and their automated laboratory in early 2024, we took drug discovery and development to a completely new level.

Not only did we solve current obstacles in optimization and development of complex biotherapeutic candidates, we now have an AI-driven, end-to-end automated platform, that enables development of highly efficient, safe, and multispecific biotherapeutics – similar to a Swiss army knife – at an unprecedented speed. The platform allows design and development of an unlimited number of biotherapeutics mimicking industrial production processes. This makes BioCopy a key partner for pharmaceutical industries, when it comes to bringing next-generation biotherapeutics to market.

The acquisition of Perspix Biotech marks a milestone for BioCopy on our mission to end cancer’s reign. It is the latest in a series of important acquisitions we have made in recent years. With these we have optimally aligned our business towards developing highly effecive and safe cancer drug candidates.

Our extended Team - selected CVs

At BioCopy, we are supported by a world-class Board of Directors and Scientific Advisory Board. Our advisors combine decades of leadership in global pharma, biotech, and life sciences innovation with groundbreaking academic achievements, including a Nobel Prize in Chemistry. Their diverse expertise spans oncology, immunotherapy, AI, structural biology, and antibody engineering. Together, they provide strategic guidance, ensure scientific excellence, and help shape BioCopy’s path toward developing the next generation of cancer therapeutics.

Wirtschaftswoche magazine ranks Matthias Wiedenfels among Germany's biotech pioneers of the coming decade.

Basel, Dec 6, 2024. BioCopy AG is proud to announce that the renowned WirtschaftsWoche, a medium of the Handelsblatt Media Group, has selected Matthias Wiedenfels as a winner of “Germany's 30 by 2030”. With this award, the editorial team honors 30 outstanding personalities who, through their innovative strength and commitment, are making a significant contribution to shaping Germany's future by 2030. >>read more

>> read our Press Release in German

>> to the WirtschaftWoche article

BioCopy chooses Genedata for AI-powered Multi-specific Antibody Discovery

Basel, July 17, 2024. By implementing the leading enterprise software solution for bio-pharmaceutical R&D, BioCopy takes the necessary step towards its AI-powered high-quality engineering of next-generation cancer therapeutics. >> read more

Game Changer in Fighting Cancer: BioCopy expands corporate portfolio with acquisition of Perspix Biotech GmbH

Basel, April 9, 2024. BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzer-land, today announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and robotics for the discovery and development of next-generation multispecific biotherapeutics. As part of BioCopy AG, Perspix Biotech GmbH will be renamed as BioCopy Analytix GmbH and provide analyti-cal and other services to the company group. >> read more

Press Release 2022-12-05

BioCopy patent for complex array fabrication process granted much earlier than usual: setting new standards in the state of the art for kinetic binding measurement. >> read more

Press Release 2022-03-29

BioCopy AG presents ValidaTe, a novel ultra-fast screening technology to significantly speed up drug discovery. >> read more

• WirtschaftsWoche. December 6 2024. "Wo Deutschland bei Biotech Spitze ist. Organe aus dem 3D-Drucker, eine Technologie, die Krebsherde aufspürt und ein neues Verfahren gegen Herzleiden: Deutschland sprudelt vor Biotech-Ideen." >> read more

• Wirtschaft mit Weisbach. Episode 23. "Kann KI die Krebsforschung revolutionieren?" 14. Juni 2024 >>listen in

• Market access and health policy magazine: "Den heiligen Gral der Wirkstoffentwicklung bei Biotherapeutika entdeckt". Issue 04/2024. >> read more

• Pharma Focus Europe: "Accelerating the Drug Development Process". Issue 04/2024. >> read more

• Euro Health Leaders: "Matthias Wiedenfels - Visionary Leader in Next-Gen Drug Discovery". Issue 03/2024. >> read more

Awards

• Forbes Magazine listed BioCopy in 2021 as one of the 30 Spin-offs to watch (https://www.forbes.at/artikel/spin-offs-to-watch-2021.html)
• The Royal Society of Chemistry (RSC) Emerging Technologies of London lists the BioCopy concepts “AptaSWIFT” and “immune2day” in the TOP 10 of Health technologies in 2015 (during early spin-off phase)

Selected Publications

• Kraemer S et al., An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions; Sci Rep. 2023; 13 (1): 5290; doi: 10.1038/s41598-023-32384-z.
• Ziegengeist T et al., High-Throughput and Format-agnostic Mispairing Assay for Multispecific Antibodies using Intact Mass Spectrometry. Anal Chem 2023; 95 (27); doi: 10.1021/acs.analchem.3c00742.
• An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics. MAbs. 2021; 13 (1):1955433; doi: 10.1080/19420862.2021.1955433.